MiMedx Group, Inc. (MDXG)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.57+3.16%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MDXG
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $4.57 MDXG trades at 24× p/e, in line with its 22× p/e peer median, and our $4.55 fair value agrees. We hold it with low confidence: our number sits well below the analyst range and it trades at 1.9× its own p/e history. Analysts target $7.00–$8.00. Note: our $4.55 fair value sits below the entire analyst range ($7.00–$8.00). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $8.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $4.07 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $5.16 | — | — | Hist. CAGR | high |
| graham number | 12M | $2.50 | — | — | TTM | high |
| Peer P/FCF | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$7.00 – $8.00 (median $8.00) · 3 analysts · as of 2026-08-27
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Roughly priced in line with peers.
Richer than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $5.93 |
| 21.6 |
| 0.27 |
| TTM |
| high |
| Peer P/E | 12M | $4.18 | 22.0 | 0.19 | TTM | high |
| Peer P/S | 12M | $27.35 | 11.4 | 2.40 | TTM | high |
| residual income | 12M | $1.72 | — | — | TTM | high |
| Own P/E history | 12M | $2.47 | 13.0 | 0.19 | TTM | high |
| triangulated | 12M | $4.32 | 22.0 | 0.20 | Triangulated | high |
| Peer P/E | 3Y | $2.87 | 22.0 | 0.13 | Hist. CAGR(prov.) | low |
| Peer P/S | 3Y | $12.70 | 11.4 | 1.12 | guidance | low |
| Own P/E history | 3Y | $1.69 | 13.0 | 0.13 | Hist. CAGR(prov.) | low |
| Peer P/E | 5Y | $1.72 | 22.0 | 0.08 | Hist. CAGR(prov.) | medium |
| Peer P/S | 5Y | $7.61 | 11.4 | 0.67 | guidance | medium |
| Own P/E history | 5Y | $1.01 | 13.0 | 0.08 | Hist. CAGR(prov.) | medium |